Bausch + Lomb Corporation (NYSE:BLCO) Receives $18.25 Consensus Target Price from Brokerages

Bausch + Lomb Corporation (NYSE:BLCO) has been assigned a consensus rating of “Hold” from the fifteen research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $18.25.

BLCO has been the topic of several research reports. Barclays lifted their price target on Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. HC Wainwright raised their price objective on Bausch + Lomb from $17.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Royal Bank Of Canada upped their target price on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 27th. Citigroup increased their price target on shares of Bausch + Lomb from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, Wall Street Zen lowered shares of Bausch + Lomb from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st.

Bausch + Lomb Trading Down 0.6%

NYSE:BLCO opened at $17.12 on Friday. The company has a 50-day moving average price of $17.28 and a 200-day moving average price of $16.18. The stock has a market cap of $6.06 billion, a price-to-earnings ratio of -16.78, a P/E/G ratio of 0.73 and a beta of 0.58. The company has a current ratio of 1.55, a quick ratio of 1.04 and a debt-to-equity ratio of 0.77. Bausch + Lomb has a 12 month low of $10.45 and a 12 month high of $18.92.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, February 18th. The company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). Bausch + Lomb had a positive return on equity of 2.77% and a negative net margin of 7.06%.The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.38 billion. During the same period in the previous year, the company earned $0.25 earnings per share. Bausch + Lomb’s quarterly revenue was up 9.8% on a year-over-year basis. Equities analysts predict that Bausch + Lomb will post 0.74 EPS for the current year.

Trending Headlines about Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Multiple insiders bought stock last week, signaling management confidence: CEO Brent L. Saunders purchased 14,700 shares (~$252k), CFO Sam Eldessouky bought 4,000 shares (~$68.5k) and EVP A. Robert D. Bailey acquired 14,600 shares (~$250k). These additions raise insider ownership and are typically viewed as a bullish signal for investors. Form 4 — Saunders Form 4 — Eldessouky Form 4 — Bailey
• Positive Sentiment: Short interest declined ~15.9% in February (to ~2.66M shares), lowering the days-to-cover to ~4.5 — a reduction in bearish positioning that can remove a source of selling pressure and support the share price. (Data reported in recent market updates.)
• Positive Sentiment: Bausch + Lomb launched an R&D “Teach‑in” webinar series to walk investors through its differentiated glaucoma pipeline and product roadmap — an investor-focused effort that can increase visibility of growth drivers and reduce uncertainty around the pipeline. Bausch + Lomb Launches R&D “Teach-in” Webinar Series
• Positive Sentiment: Market commentary is focusing on glaucoma-related moves and investor interest in BLCO’s pipeline — increased attention to the glaucoma franchise can be constructive if it translates to higher expectations for future sales and approvals. Bausch And Lomb Glaucoma Moves Catch Market Eyes
• Neutral Sentiment: Analysts and valuation pieces are re‑assessing BLCO following recent revenue growth and lingering net‑loss figures; these analyses can influence medium‑term expectations but are not an immediate directional catalyst. Assessing Bausch + Lomb Valuation

Insider Activity

In related news, CEO Brent L. Saunders acquired 14,700 shares of the stock in a transaction on Friday, March 6th. The stock was acquired at an average price of $17.14 per share, for a total transaction of $251,958.00. Following the completion of the purchase, the chief executive officer owned 966,575 shares of the company’s stock, valued at $16,567,095.50. This represents a 1.54% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sam Eldessouky bought 4,000 shares of the company’s stock in a transaction on Friday, March 6th. The stock was bought at an average cost of $17.13 per share, for a total transaction of $68,520.00. Following the completion of the acquisition, the chief financial officer directly owned 403,130 shares of the company’s stock, valued at approximately $6,905,616.90. This represents a 1.00% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 33,300 shares of company stock worth $570,868. Insiders own 0.15% of the company’s stock.

Hedge Funds Weigh In On Bausch + Lomb

Several institutional investors and hedge funds have recently modified their holdings of BLCO. Northwestern Mutual Wealth Management Co. boosted its stake in Bausch + Lomb by 729.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after purchasing an additional 2,042 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Bausch + Lomb by 104.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after purchasing an additional 1,136 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Bausch + Lomb by 31.2% in the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after buying an additional 1,403 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in Bausch + Lomb by 55.3% in the third quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company’s stock worth $132,000 after buying an additional 3,246 shares during the last quarter. Finally, Focus Partners Wealth bought a new position in shares of Bausch + Lomb in the third quarter worth approximately $170,000. 11.07% of the stock is currently owned by institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.